This article was displayed on the ChosunBiz MoneyMove (MM) website at 5:19 p.m. on Mar. 10, 2026.
Korea Investment Holdings' insurance M&A calculus is getting complicated. KDB Life Insurance, which had been the top priority under review, shows no sign of starting a sale process, while the main bidding for YeByeol Non-Life Insurance (formerly MG Non-Life Insurance) is just around the corner. On top of that, another option, Lotte Non-Life Insurance, has been caught up in a financial authority risk, making it even more complex for Korea Investment Holdings to decide which asset to bet on.
According to the investment banking (IB) industry on the 10th, the main bid for YeByeol Non-Life Insurance is scheduled for Apr. 6. It was originally slated for late March but has been delayed. In the preliminary bid in January, Korea Investment Holdings, Hana Financial Group, and private equity fund (PEF) manager JC Flowers were said to have submitted letters of intent, according to reports.
The market has been watching Korea Investment Holdings' choice. It is considered the most committed genuine bidder among the three, with the strongest intention to acquire an insurer. JC Flowers previously threw its hat in the ring for ABL Life Insurance and KDB Life Insurance, but it is known more as a manager primarily aiming to conduct due diligence on domestic insurer assets rather than as a genuine bidder.
It is no exaggeration to say that Korea Investment Holdings has reviewed every insurer on the M&A market. It has now narrowed the candidates to three—YeByeol Non-Life Insurance, KDB Life Insurance, and Lotte Non-Life Insurance—and is conducting a comparative analysis. With the main bid for YeByeol Non-Life Insurance less than a month away, Korea Investment Holdings can no longer afford to delay its decision.
YeByeol Non-Life Insurance's strength is that it can be acquired with relatively little money. Its current net worth is minus (-) 500 billion won, but in the industry, there is talk that the Korea Deposit Insurance Corporation (KDIC), the seller, may support about 1 trillion won to normalize YeByeol Non-Life Insurance. To reach a K-ICS ratio of 130%, the financial authority's recommended level, 1.3 trillion won is needed, and KDIC is said to be committed to covering a substantial portion of that.
If KDIC support materializes, YeByeol Non-Life Insurance's net worth would be 500 billion won. If 300 billion won is invested to acquire YeByeol Non-Life Insurance, from Korea Investment & Securities Co.'s perspective, it would be like spending 300 billion won to obtain an insurer with 800 billion won in net worth.
An IB industry official said, "If Korea Investment & Securities Co. acquires YeByeol Non-Life Insurance, it would immediately be able to manage 1.3 trillion won in cash," adding, "For 300 billion won, it can secure an insurer license and assets in the trillion-won range, making it a cost-effective option."
However, it is said that Korea Investment Holdings' greatest interest had been in KDB Life Insurance. Compared with non-life insurers, life insurers are much larger in asset size and are more effective in securing long-term operating assets.
But KDB Life Insurance has not even officially selected a sale manager, nor has it begun full-fledged sale procedures such as distributing a teaser letter. With KDB Industrial Bank Chairman Park Sang-jin recently saying that selling KDB Life Insurance is not urgent and that normalization should come first, Korea Investment & Securities Co., which had been waiting only for the sale of KDB Life Insurance to begin, has been put in a difficult position.
An IB industry official said, "With the main bid schedule for YeByeol Non-Life Insurance approaching as planned, Korea Investment & Securities Co. can no longer crane its neck waiting for KDB Life Insurance to come onto the M&A market," adding, "In the end, the key has become 'timing' rather than the 'quality' of the asset."
Meanwhile, with Lotte Non-Life Insurance also entangled in financial authority risk, Korea Investment & Securities Co.'s calculus has become even more complex. Lotte Non-Life Insurance had been evaluated as a quality asset for some time as the only profitable company among the three, but the situation changed after it received a management improvement request from the financial authorities. On the 4th, the Financial Services Commission judged Lotte Non-Life Insurance's capital adequacy improvement plan insufficient and resolved to issue a management improvement request. For potential buyers of Lotte Non-Life Insurance, this means they must factor in an additional capital raise burden on top of the acquisition price.
Applying the financial authorities' standards, Lotte Non-Life Insurance would need to raise about 300 billion won through a rights offering. In that case, it would be difficult to apply the existing valuation as-is to Lotte Non-Life Insurance's price tag. The price of existing shares would also need to be recalculated.
The industry believes that if the sale of KDB Life Insurance continues to be delayed, Korea Investment & Securities Co. is likely to first move to acquire one of the two non-life insurer assets. It could then watch market conditions and additionally consider acquiring KDB Life Insurance, a life insurer.
Acquiring more than one insurer would increase the funding burden, but from a financial holding company's standpoint, there is indeed synergy potential. Non-life and life insurance differ in business structure and asset characteristics, so having both sectors can create synergy in portfolio diversification and operations. Non-life insurers can secure a profit base centered on risk coverage such as auto insurance and long-term insurance, while life insurers can secure long-term protection products and stable operating assets.